Nantkwest (NASDAQ:NK) Shares Down 7.3%

Shares of Nantkwest Inc (NASDAQ:NK) were down 7.3% on Tuesday . The company traded as low as $1.41 and last traded at $1.40, approximately 4,391 shares traded hands during mid-day trading. A decline of 98% from the average daily volume of 177,252 shares. The stock had previously closed at $1.51.

Separately, ValuEngine cut shares of Nantkwest from a “buy” rating to a “hold” rating in a research report on Friday.

The business’s 50 day simple moving average is $1.22 and its 200 day simple moving average is $1.19. The company has a current ratio of 5.72, a quick ratio of 5.72 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $169.19 million, a PE ratio of -1.15 and a beta of 2.52.

Nantkwest (NASDAQ:NK) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. Nantkwest had a negative net margin of 164,604.89% and a negative return on equity of 44.91%. The firm had revenue of $0.01 million for the quarter.

Several institutional investors have recently made changes to their positions in NK. Parametric Portfolio Associates LLC bought a new stake in shares of Nantkwest in the 2nd quarter worth about $37,000. Tower Research Capital LLC TRC grew its holdings in Nantkwest by 4,218.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 47,766 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 46,660 shares during the last quarter. Morgan Stanley grew its holdings in Nantkwest by 303.8% during the 2nd quarter. Morgan Stanley now owns 48,497 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 36,486 shares during the last quarter. Jane Street Group LLC bought a new position in Nantkwest during the 2nd quarter valued at about $92,000. Finally, Paloma Partners Management Co purchased a new stake in Nantkwest in the 2nd quarter worth about $127,000. Hedge funds and other institutional investors own 5.50% of the company’s stock.

Nantkwest Company Profile (NASDAQ:NK)

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Recommended Story: Conference Calls

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.